The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Center for cell and gene therapy to open next year – Harvard Gazette
- Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs – Barron’s
- Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline – Business Wire
- What can a 157-year-old pharma giant bring to the table of cell and gene therapies? Quite a bit, Bayer says – Endpoints News
- Pfizer backing biotechnology innovation with $120m capital outlay – BioPharma-Reporter.com
- resveratrol dr axe
- betty white angela lansbury ruth westheimer iris apfel successful aging
- medicine to reveerse or slow ageing
- insidegnss pnt machine learning
- the economist special report financing longevity
- tech crunch national grid
- where is th burrowers armor dark souls remake
- Pfizer/BioNTechs COVID-19-vaccine infertility
- Popular Mechanics
- fireside chat with ash mufareh
|Search Immortality Topics:|
Category Archives: Nano Medicine
Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution – The Hub at Johns Hopkins
ByHub staff report
Philanthropist and Johns Hopkins Medicine trustee David M. Rubenstein has made a $15 million commitment to the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins to support the department's research.
Image caption: David M. Rubenstein
The gift, his second pledge of that size to the department, will establish the David M. Rubenstein Precision Medicine Center of Excellence and will deepen his support for basic science researchers focused on the development of therapeutic approaches to preserve and restore hearing. Three strategic project teams, working in collaboration with researchers across Johns Hopkins University, will explore inner ear hair cell repair, sensory neuron repair, and nanomedicine drugs and drug delivery.
Rubenstein's gift will also support core facilities for these teams, consisting of:
Additionally, funds from this gift will support an annual conference and a speaker series.
"David's initial gift has helped Johns Hopkins researchers make important discoveries in several crucial areas related to hearing and hearing loss," said Paul B. Rothman, dean of the School of Medicine and CEO of Johns Hopkins Medicine. "But there is so much more to be done in this area, and once again, David has stepped forward. We are grateful for all that his generosity has made possible so far, and we are even more excited about what this new commitment will allow us to accomplish going forward. In the end, this work will help the millions of people who struggle every day with hearing problems."
Rubenstein's earlier gift to the department, made in 2015, funded the creation of an endowment to support cross-institutional accelerator grants. Any researcher at Johns Hopkins may apply for a grant for new or existing research to further the understanding of hearing. Grant amounts vary. In FY19, a total of $800,000 was awarded to seven different research projects, plus research core support. The earlier gift also established an endowed professorship, providing critical funds in perpetuity to support a leading faculty member in research and teaching.
"David's support has enabled innovative research projects that leverage the expertise and imagination of scientists, engineers, and clinicians from across Johns Hopkins," said Paul Fuchs, the inaugural David M. Rubenstein Research Professor of OtolaryngologyHead and Neck Surgery. "This is particularly important as we move from basic discovery of molecular and cellular mechanisms, to targeting these for therapeutic benefit. Current efforts employ gene therapy to correct inherited deafness, to regenerate cochlear hair cells, or to enhance protection from acoustic trauma. Other strategies aim to re-establish lost connections from inner ear to brain, a significant contributor to noise-induced and age-related hearing loss."
To learn more about some of the advances made possible through Rubenstein's generosity and hear from the researchers, visit the Otolaryngology-Head and Neck Surgery YouTube playlist.
Rubenstein is a founder and co-executive chairman of The Carlyle Group, a global investment firm. Rubenstein is a noted philanthropist and a long-time member of the Johns Hopkins Medicine board of trustees.
"It is a privilege to support the talented and committed researchers and doctors of Johns Hopkins who are helping people suffering from hearing loss," Rubenstein said. "I am impressed with the progress made in recent years and hope this new gift will accelerate and deepen those efforts."
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – LionLowdown
Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.
Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.
REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223
The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.
The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.
Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.
Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.
DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223
Scope of the Nanomedicine Market:
Nanomedicine Market by Modality:
Diagnostics TreatmentsNanomedicine Market by Diseases:
Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:
Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:
Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:
Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.
MAJOR TOC OF THE REPORT
Chapter One: Nanomedicine Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Nanomedicine Market Competition, by Players
Chapter Four: Global Nanomedicine Market Size by Regions
Chapter Five: North America Nanomedicine Revenue by Countries
Chapter Six: Europe Nanomedicine Revenue by Countries
Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries
Chapter Eight: South America Nanomedicine Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries
Chapter Ten: Global Nanomedicine Market Segment by Type
Chapter Eleven: Global Nanomedicine Market Segment by Application
Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)
Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Name: Vikas Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Contact: +919607065656/ +919607195908
This article was originally published here
Med Res Rev. 2020 Dec 21. doi: 10.1002/med.21759. Online ahead of print.
Targeted delivery by either passive or active targeting of therapeutics to the bone is an attractive treatment for various bone related diseases such as osteoporosis, osteosarcoma, multiple myeloma, and metastatic bone tumors. Engineering novel drug delivery carriers can increase therapeutic efficacy and minimize the risk of side effects. Developmnet of nanocarrier delivery systems is an interesting field of ongoing studies with opportunities to provide more effective therapies. In addition, preclinical nanomedicine research can open new opportunities for preclinical bone-targeted drug delivery; nevertheless, further research is needed to progress these therapies towards clinical applications. In the present review, the latest advancements in targeting moieties and nanocarrier drug delivery systems for the treatment of bone diseases are summarized. We also review the regeneration capability and effective delivery of nanomedicines for orthopedic applications.
PMID:33347711 | DOI:10.1002/med.21759
US Virtual 3D Nanorobots Market 2020: Deep Analysis of Current Trends and Future Demand by Top Key Players are Gingko Bioworks, Synthace, Zymergen…
Virtual 3D Nanorobots Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025Increasing prevalence of chronic diseases and rising adoption of technologically advanced medical equipments drive the growth of global virtual 3D nanorobots Market.
Get Sample Copy of The Activated Alumina Market Report 2020@ https://brandessenceresearch.com/requestSample/PostId/555
*The sample pages of this report is immediately accessible on-demand.**
Scope of Global Virtual 3D Nanorobots Market Report-
Nanorobots are nano electromechanical systems designed to perform a specific task with precision at nano scale dimensions. It will be mainly used for the treatment in field of nanomedicine. An interesting utilization of nanorobots may be their attachment to transmigrating inflammatory cells or WBC, to reach inflamed tissues and assist in their healing process. It can also used for biomedical instrumentation, early diagnosis and targeted drug delivery for cancer, pharmacokinetics, surgery, monitoring of diabetes and health care. Virtual 3D nanorobots are expected to provide personalized treatments with improved efficacy and reduced side effects that are not available today. Virtual 3D nanorobots can be used to treat genetic diseases by comparing the molecular structures of both DNA and proteins found in the cell to known or desired reference structures. Some of its potential applications are; early diagnosis and targeted drug delivery for cancer biomedical instrumentation, pharmacokinetics, monitoring of diabetes, surgery and others. Another possible application can be the capability to locate atherosclerotic lesions in stenosed blood vessels, particularly in the coronary circulation, and treat them either mechanically, chemically or pharmacologically.
Virtual 3D nanorobots marketreport is segmented on the basis of type, application, distribution channel and region & country level. Based upon type, global virtual 3D nanorobots market is classified into microbivore nanorobots, respirocyte nanorobots, clottocyte nanorobots. Based upon application, global virtual 3D nanorobots market is divided into dentistry, emerging drug delivery, brain aneurysm, cancer detection, gene therapy, nanomedicine, biomedical, healthcare and others.
The regions covered in this Virtual 3D Nanorobots Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of Virtual 3D Nanorobots is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Some major key players for Global Virtual 3D Nanorobots Market Gingko Bioworks, Synthace, Zymergen Inc., Advanced Diamond Technologies and Advanced Nano Products Co. Limited and others.
Increasing Prevalence of Chronic Diseases and Rising Adoption of Technologically Advanced Medical Equipments Drive the Growth of Global Virtual 3D Nanorobots Market
Nanorobots are expected to provide new treatments for the patients suffering from different diseases. Latest developments in the field of biomolecular computing have demonstrated the feasibility of processing logic tasks by bio-computers. The major factor driving the growth of global virtual 3D nanorobots market is increasing adoption of technologically advanced products in healthcare coupled with the rising government initiatives in this field. In addition, increasing prevalence of chronic diseases, improving healthcare infrastructure and technological advancements to develop more innovative, better and effective medical treatments are also anticipated to foster the market growth within the forecast period. In recent years, the potential of nanotechnology motivated many governments to devote significant resources to this new field. The U.S. National Science Foundation launched a program in Scientific Visualization in part to harness supercomputers in picturing the nanoworld. Firms such as; IBM, PARC, Hewlett Packard, Bell Laboratories, and Intel Corp. and others are collaborating to produce new nano products.
Cancer can be successfully treated with current stages of medical technologies and therapy tools. One of the important aspect to achieve a successful treatment for cancer patients is the development of efficient targeted drug delivery to decrease the side effects from chemotherapy. Nanorobots can help on such extremely important aspects of cancer therapy owing to the properties of nanorobots to navigate as blood borne devices. Nanorobots with embedded chemical biosensors can be used to perform detection of tumour cells in early stages of development inside the patients body. Thus all these advantages of nanorobots are expected to boost the market growth.
However, lack of trained professional may hamper the market growth. In spite of that, increasing advancements in the field can provide various opportunities for the further growth of the market. The use of nanorobots may advance biomedical intervention with minimally invasive surgeries and help patients who need constant body functions monitoring, or ever improve treatments efficiency through early diagnosis of possible serious diseases.
North America is Expected to Dominate the Global Virtual 3D Nanorobots Market
The global virtual 3D nanorobots market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the global virtual 3D nanorobots market within the forecast period attributed to the highly developed healthcare infrastructure and increasing adoption of new technologies in healthcare in this region. In addition, increasing government initiative in this field are also supplementing the growth of virtual 3D nanorobots market in this region. Asia Pacific is anticipated to witness a significant growth in global Virtual 3D Nanorobots market owing to emerging economies and growing awareness about nanorobotics in healthcare. In addition, improving healthcare infrastructure due to the favourable government initiatives regarding health are also expected to foster the growth of virtual 3D nanorobots market in this region within the forecast period.
Key Benefits for Market Report
Virtual 3D Nanorobots MarketSegmentation:-
By Type: Respirocyte Nanorobots, Microbivore Nanorobots, Clottocyte Nanorobots
By Application:-Dentistry, Gene therapy, Brain Aneurysm, Emerging Drug Delivery, Cancer detection, NanoMedicine, Biomedical, Healthcare, Others
By Regional & Country Analysis
North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us email@example.com
Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide…
SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.
As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.
Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.
Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.
The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (https://symposium.mndassociation.org/virtual-2020/).
About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.
About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.
About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.
About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.
Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Media ContactAndrew MielachLifeSci Communications(646) firstname.lastname@example.org
Investor ContactBruce MackleLifeSci Advisors, LLC(929) email@example.com
Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection – ResearchAndMarkets.com -…
DUBLIN--(BUSINESS WIRE)--The "Nanomedicine Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
This report describes the global market size of Nanomedicine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025. For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.
For the competitor segment, the report includes global key players of Nanomedicine as well as some small players.
The information for each competitor includes:
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Nanomedicine Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End-users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Trading Analysis
8.1 Export of Nanomedicine by Region
8.2 Import of Nanomedicine by Region
8.3 Balance of Trade
Chapter 9 Historical and Forecast Nanomedicine Market in North America (2015-2025)
9.1 Nanomedicine Market Size
9.2 Nanomedicine Demand by End Use
9.3 Competition by Players/Suppliers
9.4 Type Segmentation and Price
9.5 Key Countries Analysis
Chapter 10 Historical and Forecast Nanomedicine Market in South America (2015-2025)
10.1 Nanomedicine Market Size
10.2 Nanomedicine Demand by End Use
10.3 Competition by Players/Suppliers
10.4 Type Segmentation and Price
10.5 Key Countries Analysis
Chapter 11 Historical and Forecast Nanomedicine Market in Asia & Pacific (2015-2025)
11.1 Nanomedicine Market Size
11.2 Nanomedicine Demand by End Use
11.3 Competition by Players/Suppliers
11.4 Type Segmentation and Price
11.5 Key Countries Analysis
11.5.4 South Korea
Chapter 12 Historical and Forecast Nanomedicine Market in Europe (2015-2025)
12.1 Nanomedicine Market Size
12.2 Nanomedicine Demand by End Use
12.3 Competition by Players/Suppliers
12.4 Type Segmentation and Price
12.5 Key Countries Analysis
Chapter 13 Historical and Forecast Nanomedicine Market in MEA (2015-2025)
13.1 Nanomedicine Market Size
13.2 Nanomedicine Demand by End Use
13.3 Competition by Players/Suppliers
13.4 Type Segmentation and Price
13.5 Key Countries Analysis
13.5.3 South Africa
Chapter 14 Summary for Global Nanomedicine Market (2015-2020)